Prognostic significance of magnesium in diffuse large B-cell lymphoma: a multicenter, prospective study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400083372

Enrollment

Unknown

Registered

2024-04-23

Start date

2024-05-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma

Interventions

Case series:None

Eligibility

Sex/Gender

All

Age

14 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Age >14 years 2.The newly diagnozed diffuse large B-cell lymphoma based on pathology. 3.Each subject must sign an informed consent form (ICF) indicating that he or she fully understands the study and are willing to participate in the study. 4.Life expectancy > 6 months.

Exclusion criteria

Exclusion criteria: 1.HIV infection (HIV antibody positive). 2.DLBCL Patients with previous malignant tumors or those who have received chemotherapy. 3.Unavaible lymphoma tissue for sequencing. 4.Poor compliance or unsuitable for this study and follow-up as decided by the investigator.

Design outcomes

Primary

Measure	Time frame
Progress-free survival;	—

Secondary

Measure	Time frame
Overall survival;Treatment response;	—

Countries

China

Contacts

Public ContactJie Jin

The First Affiliated Hospital, Zhejiang University School of Medicine

1513084@zju.edu.cn+86 87236898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026